348 related articles for article (PubMed ID: 31737965)
1. The evolution of addiction treatment and harm reduction programs in Iran: a chaotic response or a synergistic diversity?
Ekhtiari H; Noroozi A; Farhoudian A; Radfar SR; Hajebi A; Sefatian S; Zare-Bidoky M; Razaghi EM; Mokri A; Rahimi-Movaghar A; Rawson R
Addiction; 2020 Jul; 115(7):1395-1403. PubMed ID: 31737965
[TBL] [Abstract][Full Text] [Related]
2. The risk environments of people who use drugs accessing two harm reduction centers in Tehran, Iran: A qualitative study.
Bastani P; Marshall BDL; Rahimi-Movaghar A; Noroozi A
Int J Drug Policy; 2019 Jan; 63():90-96. PubMed ID: 30513474
[TBL] [Abstract][Full Text] [Related]
3. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.
Jaffe JH; O'Keeffe C
Drug Alcohol Depend; 2003 May; 70(2 Suppl):S3-11. PubMed ID: 12738346
[TBL] [Abstract][Full Text] [Related]
4. Harm reduction drug policy in Israel: what has been accomplished and what still needs to be done?
Bonny-Noach H
Isr J Health Policy Res; 2019 Oct; 8(1):75. PubMed ID: 31619286
[TBL] [Abstract][Full Text] [Related]
5. "In their perception we are addicts": social vulnerabilities and sources of support for men released from drug treatment centers in Vietnam.
Tomori C; Go VF; Tuan le N; Huong NM; Binh NT; Zelaya CE; Celentano DD; Dat do T; Quan VM
Int J Drug Policy; 2014 Sep; 25(5):897-904. PubMed ID: 24857185
[TBL] [Abstract][Full Text] [Related]
6. Ups and downs of addiction harm reduction in Iran: key insights and implications for harm reduction policy and policing.
Shafiee SA; Vedadhir A; Razaghi E
Harm Reduct J; 2023 Jan; 20(1):8. PubMed ID: 36670386
[TBL] [Abstract][Full Text] [Related]
7. Drug addiction in China.
Lu L; Wang X
Ann N Y Acad Sci; 2008 Oct; 1141():304-17. PubMed ID: 18991965
[TBL] [Abstract][Full Text] [Related]
8. Profile of People Who Inject Drugs in Tehran, Iran.
Amin-Esmaeili M; Rahimi-Movaghar A; Gholamrezaei M; Razaghi EM
Acta Med Iran; 2016 Dec; 54(12):793-805. PubMed ID: 28120592
[TBL] [Abstract][Full Text] [Related]
9. Injection drug use in Rural Iran: integrating HIV prevention into iran's rural primary health care system.
Mojtahedzadeh V; Razani N; Malekinejad M; Vazirian M; Shoaee S; Saberi Zafarghandi MB; Hernandez AL; Mandel JS
AIDS Behav; 2008 Jul; 12(4 Suppl):S7-12. PubMed ID: 18521737
[TBL] [Abstract][Full Text] [Related]
10. Drug use treatment and harm reduction programs in Iran: A unique model of health in the most populated Persian Gulf country.
Alam-Mehrjerdi Z; Abdollahi M; Higgs P; Dolan K
Asian J Psychiatr; 2015 Aug; 16():78-83. PubMed ID: 26168763
[TBL] [Abstract][Full Text] [Related]
11. Descriptive Aspects of Injection Drug Users in Iran's National Harm Reduction Program by Methadone Maintenance Treatment.
Eskandarieh S; Nikfarjam A; Tarjoman T; Nasehi A; Jafari F; Saberi-Zafarghandi MB
Iran J Public Health; 2013; 42(6):588-93. PubMed ID: 23967426
[TBL] [Abstract][Full Text] [Related]
12. Addressing excess risk of overdose among recently incarcerated people in the USA: harm reduction interventions in correctional settings.
Brinkley-Rubinstein L; Cloud DH; Davis C; Zaller N; Delany-Brumsey A; Pope L; Martino S; Bouvier B; Rich J
Int J Prison Health; 2017 Mar; 13(1):25-31. PubMed ID: 28299971
[TBL] [Abstract][Full Text] [Related]
13. Effects of combination approach on harm reduction programs: the Taiwan experience.
Lin T; Chen CH; Chou P
Harm Reduct J; 2016 Jul; 13(1):23. PubMed ID: 27377896
[TBL] [Abstract][Full Text] [Related]
14. Contested space in the pharmacy: public attitudes to pharmacy harm reduction services in the West of Scotland.
Gidman W; Coomber R
Res Social Adm Pharm; 2014; 10(3):576-87. PubMed ID: 24021859
[TBL] [Abstract][Full Text] [Related]
15. Public policy, attitudes and willingness to pay for treatment of substance dependence in Iran.
Ahmadian Moghaddam S; Mazyaki A; Razaghi EM
Int J Drug Policy; 2019 Dec; 74():84-89. PubMed ID: 31585318
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring and tackling smoking and other addictions: Current situation and perspectives].
Beck F; Lermenier-Jeannet A; Nguyen-Thanh V
Bull Cancer; 2019; 106(7-8):656-664. PubMed ID: 30616838
[TBL] [Abstract][Full Text] [Related]
17. Peer-delivered harm reduction and recovery support services: initial evaluation from a hybrid recovery community drop-in center and syringe exchange program.
Ashford RD; Curtis B; Brown AM
Harm Reduct J; 2018 Oct; 15(1):52. PubMed ID: 30348170
[TBL] [Abstract][Full Text] [Related]
18. Opioid Use Among Those Who Have Criminal Justice Experience: Harm Reduction Strategies to Lessen HIV Risk.
Brinkley-Rubinstein L; Cloud D; Drucker E; Zaller N
Curr HIV/AIDS Rep; 2018 Jun; 15(3):255-258. PubMed ID: 29752698
[TBL] [Abstract][Full Text] [Related]
19. Transition to injection amongst opioid users in Iran: implications for harm reduction.
Malekinejad M; Vazirian M
Int J Drug Policy; 2012 Jul; 23(4):333-7. PubMed ID: 21996166
[TBL] [Abstract][Full Text] [Related]
20. The impact of harm reduction on HIV and illicit drug use.
Ti L; Kerr T
Harm Reduct J; 2014 Feb; 11():7. PubMed ID: 24559062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
